{"id":"NCT00174265","sponsor":"Organon and Co","briefTitle":"6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)","officialTitle":"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2009-04","completion":"2009-05","firstPosted":"2005-09-15","resultsPosted":"2010-07-05","lastUpdate":"2022-02-09"},"enrollment":196,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"asenapine","otherNames":[]},{"type":"DRUG","name":"olanzapine","otherNames":["Zyprexa"]}],"arms":[{"label":"asenapine","type":"EXPERIMENTAL"},{"label":"olanzapine","type":"ACTIVE_COMPARATOR"}],"summary":"This is an extension study of A7501013 (P05771/NCT00145496) to further test\n\nthe efficacy and safety of Asenapine compared with a\n\nmarketed agent (olanzapine) in the treatment of patients with\n\npersistent negative symptoms of schizophrenia.","primaryOutcome":{"measure":"Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score","timeFrame":"Baseline of A7501013 to Day 365","effectByArm":[{"arm":"Asenapine","deltaMin":61.5,"sd":1.37},{"arm":"Olanzapine","deltaMin":60.3,"sd":1.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0148"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22198451"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":85},"commonTop":["Weight Increased","Insomnia","Nasopharyngitis","Headache"]}}